[go: up one dir, main page]

MX2016000721A - Direccionamiento de antagonistas de citocinas. - Google Patents

Direccionamiento de antagonistas de citocinas.

Info

Publication number
MX2016000721A
MX2016000721A MX2016000721A MX2016000721A MX2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A MX 2016000721 A MX2016000721 A MX 2016000721A
Authority
MX
Mexico
Prior art keywords
targeting
cytokine
cytokine antagonists
antibody
fusion protein
Prior art date
Application number
MX2016000721A
Other languages
English (en)
Other versions
MX375426B (es
Inventor
Tavernier Jan
Zabeau Lennart
Uzé Gilles
Paul Franciane
Bordat Yann
Garcin Geneviève
Original Assignee
Vib Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw filed Critical Vib Vzw
Publication of MX2016000721A publication Critical patent/MX2016000721A/es
Publication of MX375426B publication Critical patent/MX375426B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una proteína de fusión, que comprende un antagonista de citocina y un resto de direccionamiento, preferentemente, a un anticuerpo o una molécula similar a anticuerpo. En una modalidad preferida, el antagonista de citocina es una citocina modificada que se une al receptor, pero no induce la señalización del receptor. La invención además se refiere a una proteína de fusión de acuerdo con la invención para utilizar en el tratamiento del cáncer o trastornos relacionados con la inflamación o el sistema inmunitario.
MX2016000721A 2013-07-19 2014-07-01 Direccionamiento de antagonistas de citocinas. MX375426B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13306045 2013-07-19
PCT/EP2014/063976 WO2015007520A1 (en) 2013-07-19 2014-07-01 Targeting of cytokine antagonists

Publications (2)

Publication Number Publication Date
MX2016000721A true MX2016000721A (es) 2016-09-07
MX375426B MX375426B (es) 2025-03-06

Family

ID=48874233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000721A MX375426B (es) 2013-07-19 2014-07-01 Direccionamiento de antagonistas de citocinas.

Country Status (11)

Country Link
US (5) US9732135B2 (es)
EP (1) EP3022230B1 (es)
JP (1) JP6475712B2 (es)
KR (1) KR102305608B1 (es)
CN (1) CN105658669A (es)
AU (1) AU2014292355B2 (es)
CA (1) CA2918119C (es)
IL (1) IL243459B (es)
MX (1) MX375426B (es)
SG (2) SG10202010429YA (es)
WO (1) WO2015007520A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861927C (en) * 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
AU2014292355B2 (en) * 2013-07-19 2019-08-01 Centre Hospitalier Regional Universitaire De Montpellier Targeting of cytokine antagonists
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
DK3411065T3 (da) 2016-02-05 2021-07-05 Orionis Biosciences BV Clec9a-bindingsmidler
CA3016589A1 (en) * 2016-03-07 2017-09-14 Vib Vzw Cd20 binding agents and uses thereof
EP3426278B1 (en) * 2016-03-07 2024-01-03 Vib Vzw Cd20 binding single domain antibodies
US11753463B2 (en) * 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
JP7105200B2 (ja) 2016-05-13 2022-07-22 オリオニス バイオサイエンシズ ビーブイ 標的突然変異体インターフェロン－ベータおよびその使用
CA3040802A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
AU2018216032B2 (en) 2017-02-06 2022-04-07 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
EP3580230A1 (en) 2017-02-07 2019-12-18 VIB vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
CN111511763B (zh) 2017-08-09 2024-05-31 奥里尼斯生物科学有限公司 Cd8结合剂
US12091463B2 (en) 2017-08-09 2024-09-17 Orionis Biosciences, Inc. Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CA3108795A1 (en) 2018-08-08 2020-02-13 Orionis Biosciences, Inc. Sirp1a targeted chimeric proteins and uses thereof
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
JP7773371B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド Ｃｌｅｃ９ａベースキメラタンパク質複合体
US20220241376A1 (en) 2019-07-18 2022-08-04 Enyo Pharma Method for decreasing adverse-effects of interferon
US20240199750A1 (en) 2021-03-26 2024-06-20 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
CA3218793A1 (en) 2021-06-09 2022-12-15 Laurent Gauthier Multispecific proteins binding to nkp46, a cytokine receptor, a tumour antigen and cd16a
EP4573110A1 (en) 2022-08-18 2025-06-25 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024238415A1 (en) 2023-05-12 2024-11-21 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
ATE298367T1 (de) * 1996-04-26 2005-07-15 Beth Israel Hospital Interleukin-15 antagoniste
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
WO2006053883A1 (en) 2004-11-18 2006-05-26 Vib Vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
WO2007000769A2 (en) * 2005-06-29 2007-01-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science RECOMBINANT INTERFERON α2 (IFNα2) MUTANTS
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2160401B1 (en) * 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
KR101759460B1 (ko) 2007-09-21 2017-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 표적화된 인터페론이 강력한 아폽토시스 및 항-종양 활성을 발휘함
WO2010030671A1 (en) * 2008-09-09 2010-03-18 University Of Medicine And Dentistry Of New Jersey Type i interferon antagonists
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
ES2547121T3 (es) 2008-12-08 2015-10-01 Complix N.V. Proteínas de superhélice antiparalela de una sola cadena
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
NZ756727A (en) * 2011-10-28 2022-12-23 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CA2861927C (en) * 2012-01-20 2021-01-26 Vib Vzw Targeted mutant alpha-helical bundle cytokines
HUE049945T2 (hu) 2012-03-03 2020-11-30 Immungene Inc Módosított antitest-interferon mutáns fúziós molekulák
AU2014292355B2 (en) * 2013-07-19 2019-08-01 Centre Hospitalier Regional Universitaire De Montpellier Targeting of cytokine antagonists

Also Published As

Publication number Publication date
CA2918119C (en) 2022-11-29
SG11201600165WA (en) 2016-02-26
MX375426B (es) 2025-03-06
CA2918119A1 (en) 2015-01-22
US20210238247A1 (en) 2021-08-05
US10072059B2 (en) 2018-09-11
AU2014292355B2 (en) 2019-08-01
US20180334489A1 (en) 2018-11-22
US20180057555A1 (en) 2018-03-01
US10947288B2 (en) 2021-03-16
KR20160108292A (ko) 2016-09-19
IL243459A0 (en) 2016-03-31
SG10202010429YA (en) 2020-11-27
US20180334488A1 (en) 2018-11-22
JP6475712B2 (ja) 2019-02-27
WO2015007520A1 (en) 2015-01-22
KR102305608B1 (ko) 2021-09-28
CN105658669A (zh) 2016-06-08
EP3022230A1 (en) 2016-05-25
US20160159875A1 (en) 2016-06-09
JP2016529232A (ja) 2016-09-23
US9732135B2 (en) 2017-08-15
EP3022230B1 (en) 2019-11-06
IL243459B (en) 2019-10-31
AU2014292355A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
MX2016000721A (es) Direccionamiento de antagonistas de citocinas.
UY35399A (es) Conjugados de fármacos con anticuerpos
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CL2017001217A1 (es) Conjugados de droga de anticuerpos.
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
CO2018004315A2 (es) Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2
MX2019001469A (es) Tratamiento del cáncer usando un receptor de antígeno quimérico en combinación con un inhibidor de una molécula de macrófago pro- m2.
TN2015000396A1 (en) Antibody drug conjugates
DOP2017000031A (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso
MX2017006286A (es) Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
MX377844B (es) Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EA201690992A1 (ru) Антитела, специфичные к fcrn
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
CL2018000298A1 (es) Anticuerpos anti-cd154 y métodos de uso de estos.
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
MX2015016304A (es) Proteinas de union al antigeno del receptor de oncostatina m.
MX2018000548A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana.
MX377190B (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CR20160593A (es) Anticuerpos antagonistas del interferon alfa y omega

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SULZER MANAGEMENT AG

FG Grant or registration